ALK and non-small cell lung carcinoma: A case study involving a patient with ALK+ NSCLC, a condition often initially responsive to TKIs but prone to eventual drug resistance, reported that the patient, who had undergone multiple lines of TKI treatment, disclosed promising therapeutic outcomes when treated with a combination of SBRT and pneumococcal conjugate vaccine (PCV) (168).